Needham & Company Downgrades ArQule (ARQL) to Hold, Following Acquisition Dec 9, 2019 03:18PM
ArQule (ARQL) PT Raised to $13 at Needham & Company Oct 30, 2019 12:19PM
ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares Jun 27, 2019 01:09PM
ArQule (ARQL) Prices 9.25M Share Common Offering at $9.75/Sh Jun 25, 2019 07:01AM
ArQule Announces Pricing of $90 Million Public Offering of Common Stock Jun 25, 2019 07:00AM
View Older Stories

Jun 18, 2019 09:33AM Pre-Open Movers 06/18: (MGI) (PHAS) (BYND) Higher; (BHVN) (RMTI) (UBX) (more...)
Jun 14, 2019 11:58AM ArQule (ARQL) PT Raised to $11 at Needham & Company
May 1, 2019 11:28AM ArQule (ARQL) PT Raised to $9 at Needham & Company
Apr 2, 2019 07:00AM ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019
Mar 7, 2019 01:44PM Needham & Company Reiterates Bullish View on ArQule (ARQL) as Partial Response Seen in C481S Mutant Patient with ARQ-531
Jan 24, 2019 09:20AM Pre-Open Stock Movers 1/24: (AZPN) (XLNX) (LRCX) Higher; (BGG) (MKC) (UMPQ) Lower (more...)
Jul 13, 2018 04:01PM ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
Jul 11, 2018 07:01AM ArQule (ARQL) Prices 11M Share Common Offering at $5.50/Sh
Jul 11, 2018 07:00AM ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock
Jul 10, 2018 04:12PM ArQule (ARQL) Announces Commencement of Proposed Public Offering of Common Stock
Jul 10, 2018 04:12PM ArQule Announces Commencement of Proposed Public Offering of Common Stock
Jun 15, 2018 09:06AM ArQule (ARQL) PT Raised to $7 at Needham & Company; 'Early Signs of Clinical Activity for ARQ-531'
May 7, 2018 12:28PM ArQule (ARQL) PT Raised to $6 at Needham & Company; See Further Upside
Apr 17, 2018 12:47PM Needham Says ArQule's (ARQL) Derazantinib Partnership a Double Positive
Mar 20, 2018 07:00AM ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018
Dec 14, 2017 07:15AM Needham & Company Upgrades ArQule (ARQL) to Buy
Mar 28, 2017 07:00AM ArQule to Present at the 16th Annual Needham Healthcare Conference on April 4, 2017
Apr 5, 2016 07:30AM ArQule to Present at the 15th Annual Needham Healthcare Conference on April 12, 2016
Apr 7, 2015 08:30AM ArQule, Inc. to Present at 14th Annual Needham Healthcare Conference
Oct 2, 2012 03:29PM Needham & Company Downgrades ArQule (ARQL) to Hold
Apr 12, 2011 07:39AM Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
Mar 2, 2011 07:46AM Needham & Company Reiterates a 'Buy' on ArQule (ARQL); Tivantinib (ARQ 197) Phase 3 Trial Makes ArQule a Late-Stage Co.; Other Expected 2011 Catalysts May Attract Additional Attention
Jan 5, 2011 08:01AM Needham & Company Reiterates a 'Buy' on ArQule (ARQL); Pivotal Phase 3 Trial of c-Met Inhibitor ARQ 197 in NSCLC to Start Soon
Oct 11, 2010 11:52AM Needham & Company Reiterates a 'Buy' on ArQule Inc. (ARQL); ESkiMO Pie Time for ArQule, As Foil Unwrapped at the Congress Reveals Encouraging New/Maturing Phase 2 ARQ 197 NSCLC Data
Aug 5, 2010 08:03AM Needham & Company Reiterates a 'Buy' on ArQule Inc. (ARQL); Join Phase 3 Club After Robust Phase 2 ARQ 197 NSCLC Data
May 21, 2010 10:25AM 2010 ASCO Meeting Preview - Needham & Co Highlights ArQule (ARQL), Celldex (CLDX), Pharmacyclics (PCYC), and Seattle Genetics (SGEN)
Mar 31, 2010 12:22PM Needham & Company Comments On ArQule (ARQL) After Succesful Cancer Drug Trial and Surge In the Stock
Jul 23, 2009 10:01AM Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)
View Older Stories